Please login to the form below

Not currently logged in
Email:
Password:

David Meek leaves Novartis to join Endocyte as first chief commercial officer

Joins shortly after major oncology deal with Merck & Co

US biopharma company Endocyte has appointed Novartis' David Meek to the newly created role of chief commercial officer.

Meek leaves Novartis after more than seven years at the Swiss pharma firm where he was most recently the head of northern and central Europe oncology.

Previously, he served as president and CEO of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products, and he also served as the global business franchise head for Novartis' respiratory and dermatology franchise in Basel, Switzerland.

In his new role, Meek will be responsible for the development of Endocyte's commercial team and the company's overall commercial strategy and execution, which includes the deal with Merck & Co made in April, 2012, involving Endocyte's cancer drug vintafolide.

In addition to this drug, Endocyte's products in development include etarfolatide and other targeted small molecule drug conjugates.

"I'm very excited to join the Endocyte team, where I have been compelled by the company's approach to develop innovative therapies accompanied by companion diagnostics," said Meek.

Prior to his time at Novartis, Meek spent 15 years at Johnson & Johnson (J&J), where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

30th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
E-lixir Consulting

E-lixir offers digital solutions and consulting for events and trainings. We design the most customised applications for congresses, events, sales...

Latest intelligence

Leveraging HCP Transparency Insights to Drive Future Customer Investments
EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness...
How did pharma use Twitter at #ASCO16?
Each year, ASCO’s Annual Meeting brings together 30,000 oncology professionals from around the world, here we explore the #ASCO16 hashtag and how pharma utilised the channel during this year's event....
WHITE PAPER: How to engage with HCPs more effectively
Shrinking budgets and limitations on the time HCPs can spend with sales reps is making traditional engagement methods more and more ineffective. So, in order to reach the unreachable, pharma...

Infographics